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Research in plant biology entered a disruptive phase in the early 1980s with the advent of straightforward methods for the stable transformation of plant cells, allowing for the introduc-
tion of foreign DNA into the host genome1–3. There followed an 
explosion of interest in and uptake of this new technology, as the 
game-changing potential for plant sciences and agriculture became 
apparent. Among the first examples of successful plant genetic engi-
neering, also known as genetically modified, crops were those for 
tolerance to herbicides such as glyphosate4, with this innovation 
forming the cornerstone of the nascent agricultural biotechnol-
ogy industry. Similarly, the demonstration that transgenic expres-
sion of Cry proteins from Bacillus thuringiensis could inhibit insect 
herbivory showed the power to transform crop protection5. These 
two traits, individually and in combination, now represent >99% 
of the ~180 Mha land growing genetic-modification (GM) crops 
across the planet6 and some of the fastest examples of technological 
innovation and uptake in the agricultural sector.



Given the potential of plant genetic engineering and the freedom 
it can bring from dependence on traditional breeding to introduce 
variation, it is surprising that similar advances are not so apparent for 
the GM plants in which nutritional composition has been improved. 
Such traits, sometimes called output traits (since they result in an 
alteration to the harvested product), also generally deliver a benefit 
to the consumer, as opposed to delivering to the specific needs of 
the farmer (the case with the input traits of herbicide tolerance and 
insect resistance). Why do we not yet see any nutritionally enhanced 
GM crops being commercially grown in the field? Perhaps this is 
because nutritional quality, unlike herbicide tolerance, is a more 
difficult trait to quantify and demonstrate its efficacy, as well as 
being more genetically complex than these single-gene input traits. 
Nutritional enhancement can be achieved in different ways but for 
the purpose of this short article we have defined it as the addition or 
elevation of a nutrient in a foodstuff through GM, as distinct from 
other forms of plant breeding or direct supplementation7.
On the basis of the success of the input traits, we know that 
the underpinning technology works well and at multiple scales. 
Q1 Q2 Q3 Q4
Equally, pre-existing supporting agricultural infrastructures are 
easily adapted (with low additional costs) to handling a GM crop. 
Yet the problems of malnutrition and poor diet remain for many 
populations, with more problems coming to the fore. The Green 
Revolution helped to lift many millions of people out of starva-
tion but now of greater concern are metabolic pathologies such as 
type-2 diabetes, obesity and cardiovascular disease, arising from 
the over-consumption of calorie-rich but nutritionally poor food-
stuffs7. This review considers not only the progress towards devel-
oping nutritionally enhanced GM crops but also looks at some of 
the other issues that have contributed to delaying these innovations. 
Specifically, we consider two well-known examples, Golden Rice 
and omega-3 fish oil crops, in terms of benefit against opposition, 
posing the question—if not now, when? Will it ever be feasible to 
deliver nutritional enhancement through GM crops? 

On the wider 
issue of other emerging examples of GM nutritional enhancement, 
the reader is pointed towards the recent review by Martin and Li 7.
Golden Rice
It is reported that the concept of Golden Rice or more precisely, rice 
endosperm rendered yellow through the engineered accumulation of 
pro-vitamin A, beta-carotene, was first suggested in 1984 (ref. 8) plac-
ing it right at the dawn of plant genetic engineering. 

However, unlike 
herbicide tolerance, the development of this trait took well over a 
decade to demonstrate even the first steps towards making a rice 
grain that could be polished and still contain beta-carotene. In 1997, 
Burkhardt et al. showed that endosperm-specific expression of the 
daffodil (Narcissus pseudonarcissus) phytoene synthase gene directed 
the accumulation of phytoene (the precursor of beta-carotene)9  
and in 2000, Ye et al. reported the first iteration of Golden Rice 10, in 
which beta-carotene was made in the grain’s endosperm. With the 
benefit of hindsight, what was hailed as a landmark achievement 
then, might now be viewed as a ‘proof-of-principle’ study but still 
this achievement represents the first step towards the development 
of output traits and nutritionally enhanced crops. In 2000, the start-
ing gun was fired on the race to make available a crop that could 
Q5
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The potential for using genetic modification (GM) to enhance the nutritional composition of crops (for either direct human 
consumption or as animal feed) has been recognized since the dawn of the GM era, with such ‘output’ traits being considered 
as distinct, if not potentially superior, to ‘input’ traits such as herbicide tolerance and insect resistance. However, whilst input 
traits have successfully been used and now form the basis of GM agriculture, output-trait GM crops are still lagging behind after 
20 years. This is despite the demonstrable benefits that some nutritionally enhanced crops would bring and the proven value 
of GM technologies. This article considers the present state of nutritional enhancement through GM, highlighting two high-
profile examples of nutritional enhancement—Golden Rice and omega-3 fish oil crops—systematically evaluating the progress, 
problems and pitfalls associated with the development of these traits. This includes not just the underlying metabolic engi-
neering but also the requirements to demonstrate efficacy and field performance of the crops and consideration of regulatory, 
intellectual property and consumer acceptance issues.
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potentially radically improve the lives of millions, lifting them out of 
vitamin A deficiency and the associated pathologies such as child-
hood blindness10. Although some technical issues remained to be 
overcome (such as the modest accumulation of beta-carotene in the 
polished grain), in the view of the inventors it was issues such as 
intellectual property rights, non-governmental organization opposi-
tion and the regulatory burden that is imposed on any GM crop 11–13 
that stalled progress of Golden Rice becoming a viable crop. 
Attempting to pilot the development of such a GM trait outside 
agriculture biotechnology companies, represented a further chal-
lenge, both in terms of costs and experience12,13. For all that, progress 
was made on many fronts, including introducing the Golden Rice 
trait into indica varieties of rice suitable for cultivation in the most 
needful geographical regions and also the development of a second 
iteration (Golden Rice 2, GR2) in which the endosperm levels of 
beta-carotene were increased at least tenfold through the replace-
ment of the daffodil phytoene synthase gene with a similar activity 
from maize14. Importantly, the development of GR2 was carried out 
in collaboration with Syngenta, allowing the project to benefit from 
this company’s experience in intellectual property rights and regula-
tory approval14. By 2005, optimism was restored with expectations 
for the crop to be approved and grown on a large scale 11–13.
Yet by the end of the same decade the programme seemed to 
have stalled. Syngenta left the project and the lack of progress was 
being questioned8,13. Would the trait (by now backcrossed into the 
indica IR64 variety) perform in the field and be safe to eat? Sadly, 
environmental releases (GM field trials) in the Philippines, essen-
tial to validate the yield of the transgenic line and also to provide 
data for regulatory approval, were destroyed by anti-GM activists 
in 2013 (refs. 12,13). At the same time, concerns emerged that the 
lead event for GR2 (GR2-R1) was not performing as well in the 
field as non-GM lines. Molecular characterization of this lead event 
GR2-R1 indicated that the transgene cassette was integrated into 
the first exon of the rice gene for OsAux1, disrupting the transport 
of auxins15. It is possible that a lack of experience in carrying out 
pre-regulatory GM field studies contributed to this delay, although 
it has been reported by one of those involved in the project that 
these molecular problems were known but not understood before 
environmental release13.
In 2017, the Philippines Rice Research Institute (PhilRice) and 
the International Rice Research Institute (IRRI) submitted applica-
tions for a biosafety permit for the direct use in food, feed or for pro-
cessing, of GR2-E1 (a back-up event produced by Syngenta14) to the 
Philippines’ Department of Agriculture-Bureau of Plant Industry, the 
US Food and Drug Administration, Food Standards Australia New 
Zealand and to Health Canada, marking an important step towards 
approval and release. Nearly 20 years after the original proof-of-
principle there is now a realistic prospect that GR2 will be approved 
for wide-scale growth and consumption; a simple intervention to lift 
millions out of a debilitating if not fatal deficiency.
Omega-3 fish oils
Interest in engineering plants to accumulate omega-3 long-chain 
polyunsaturated fatty acids (LC-PUFAs) began in the late 1990s16. 
This is because the omega-3 LC-PUFAs EPA and DHA (eicosapen-
taenoic acid and docosahexanoic acid, respectively) are known to 
play a crucial role in human health and development but are not 
present in any higher plant17. Increasing demand for EPA and 
DHA-containing oils (predominantly sourced from the oceans as 
fish oils) has raised questions about sustainability and the associ-
ated environmental footprint. Since most marine-sourced fish oils 
are used in aquaculture (fish farming), rather than for direct human 
nutrition, expansion in that sector places further demand on fish 
stocks17. Viewed from an economic perspective, the commodity 
price of fish oil is twice that of vegetable oil, making it an attractive 
trait to introduce into plants.
Unlike Golden Rice and beta-carotene, the biosynthesis of EPA 
and DHA involves many enzymes and is non-native to higher 
plants. The organisms responsible for the primary biosynthesis of 
these omega-3 LC-PUFAs are marine microbes such as microalgae, 
forming the base of the aquatic foodwebs in which these fatty acids 
accumulate at every trophic level17. Conceptually, the transfer of 
algal genes is straightforward but 20 years ago the molecular iden-
tity of these biosynthetic activities was unknown16. A phase of gene 
discovery for the desaturases and elongases required to make EPA 
and DHA resulted in a toolbox of sequences with which to attempt 
the heterologous synthesis of these omega-3 fatty acids. Initial 
attempts in both yeast and plants to make EPA resulted in disap-
pointingly low yields and revealed some metabolic bottlenecks that 
resulted from the inefficient recognition of non-native substrates by 
endogenous lipid metabolism18. These first results set the course for 
further intensive studies of this pathway in transgenic plants and 
the adoption of iterative rationales to overcome often poorly under-
stood biochemical obstacles. These advances, from several different 
research teams, have delivered plant seed oils that contain levels of 
EPA and DHA the same or greater than that found in bona fide fish 
oils19,20. More recently, field trials of GM camelina and canola accu-
mulating EPA and DHA have been carried out by several groups 
in the UK, USA and Australia20,21. Animal feeding studies in which 
the oil from GM camelina has been used to feed salmon, sea bream 
and mice have been published, confirming the efficacy of this plant-
derived source of EPA and DHA to serve as a direct drop-in replace-
ment for marine oils22,23. A substantial body of data demonstrates 
the feasibility of using these plants to generate a terrestrial, de novo 
source of omega-3 fish oils. This production platform (for example, 
transgenic camelina or canola) can service the needs of not just the 
aquafeed sector but also direct human nutrition, terrestrial ani-
mal nutrition and pharmaceutical applications, since it generates a 
chemical ‘feedstock’ (triacylglycerols containing EPA and/or DHA) 
identical in properties to the triacylglycerols that comprise fish oils.
Diversity of traits and drivers
Perhaps the most obvious differentiating factor between the Golden 
Rice trait and that for omega-3 fish oils, is that whilst the former 
was conceived as conforming to public-good/humanitarian use, the 
latter has a notable economic component, in addition to deliver-
ing nutritional and sustainability benefits. Also, as noted above, 
there is increased fiscal value associated with a plant oil that has 
been enhanced by the presence of the omega-3s EPA and DHA. 
Conversely, in the case of Golden Rice, not only is there a less obvi-
ous commercial value associated with enhanced amounts of beta-
carotene, there are strong moral imperatives (established by the 
Humanitarian Golden Rice project) to prevent ‘profiteering’ from 
vitamin-A deficiency and human misery12. Unfortunately, this can 
be viewed as putting the two output traits (Golden Rice and omega-3) 
on distinct paths, since the drivers and the end-user pull are dif-
ferent. Specifically, the desirability and value of the omega-3 trait 
is recognized by the end-users of such an oil (predominantly pri-
vate companies involved in the aquafeed sector), allowing for the 
establishment of value chains and business models based around 
economics. In the case of Golden Rice, although the absence of 
monetization is fundamental to the ethical use of the trait, the con-
comitant absence of a commercially motivated plan for its use can 
be viewed as a disadvantage. This became pertinent with the exit 
of Syngenta from the Golden Rice project in 2005 (refs. 12,13). It is 
interesting to note that multiple groups from publicly funded and 
private industry have focused on the omega-3 trait, whereas studies 
on Golden Rice have been associated with fewer teams, predomi-
nantly from the public sector. The plant omega-3 trait can only 
be achieved using a GM solution, whereas the accumulation of 
pro-vitamin A formed part of the contemporaneous conventional 
breeding HarvestPlus (www.harvestplus.org) crop biofortification 
NATuRe PlANTS | www.nature.com/natureplants
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programme (most notably orange cassava). Golden Rice faced a 
problem of consumer acceptance (in terms of technology and selec-
tion of regional varieties) that the omega-3 commodity trait does 
not. However, regulatory approval for both traits (omega-3, Golden 
Rice) is being taken forward by organizations other than those who 
established the first wave of GM input traits.
Barriers and lessons
The problems that beset the Golden Rice project occurred for the 
most part not during the research phase but in the development 
stage11,24. As identified by the Golden Rice inventors, intellectual 
property represented a major roadblock for establishing freedom-
to-operate — that is, ensuring that you do not infringe other par-
ties’ patents — and subsequent entry into the regulatory approval 
process12. However, this situation is not unique to Golden Rice and 
probably more complicated for the omega-3 trait, where the meta-
bolic engineering is considerably more complicated (more genes 
mean more patents). Also, the field has many active parties, all 
generating their own intellectual property. Several generic prob-
lems confront any entity wishing to determine their freedom-to-
operate status. First, the patent landscape for plant biotechnological 
processes is complicated and congested. Second, progress through 
the patenting process is (understandably, given the volumes) slow, 
with many complex filings still not at the granted stage after several 
years. This means that it is often hard to determine the relevance 
and breadth of a patent because the final scope of the claims has not 
yet been decreed. Moreover, the acceptance by examiners of some 
of the broad claims often included in patent applications has con-
siderably reduced over the years, meaning that grants nowadays are 
more restricted in scope. Unfortunately, this does not apply retro-
spectively to earlier patents, meaning that some older patents have a 
reach that would not be granted now.
With hindsight, it is clear that the transitioning of a project from 
a research phase onto a development pathway requires a great deal 
of planning, most of which should have occurred at a very early 
phase in the project12. However, unless the programme of work was 
initiated with the specific goal of progressing all the way through to 
regulatory approval and commercialization (as might be the case in 
industry), then lack of consideration at the start can result in prob-
lems later. For example, the use of an antibiotic resistance marker for 
the selection of transgenic plants is acceptable for laboratory-based 
research but might prove problematic when seeking approval for 
commercial release. Similarly, the use of genetic elements (promot-
ers, genes, vectors and so on) that are covered by third-party patents 
is usually without problem when used for basic research (under the 
so-called research or safe-harbour exemptions enshrined in pat-
ent law) but would require licensing if their use extended beyond 
that. This presupposes that the aim of all fundamental research is 
the generation of outputs that are suitable for translation. Even with 
the recent increased emphasis on research impact and delivery of 
tangible benefits from basic research, most projects do not have an 
applied goal. However, an awareness of the intellectual property 
landscape associated with your field of endeavour is a good thing, as 
is a basic understanding of the process by which a transgenic event 
might be evaluated for regulatory approval and commercialization. 
In the case of Golden Rice, initial research was carried out in an aca-
demic environment, in which intellectual property and regulatory 
approval were (understandably) given less consideration than the 
primary goal of making beta-carotene in the rice endosperm. For 
the omega-3 trait, the combination of a more market-driven trait 
and the presence of several companies working in this field resulted 
in greater sensitivity to these issues, although the above-mentioned 
issue of protracted time for a patent to get to grant means that free-
dom-to-operate is a continually shifting landscape. Attempts have 
been made to make aspects of intellectual property management 
easier, for example through Public Intellectual Property Resource 
for Agriculture (PIPRA) establishment of ‘patent pools’ for plant 
transformation25.
Influencing the narrative
Beyond the problems of restrictive intellectual property, expensive 
regulatory approval and the economics of business development, 
additional factors need to be considered, especially those of public 
engagement and societal consent. In the early years of the agricul-
ture biotechnology industry, with hindsight it is widely felt that this 
new technology (in the form of herbicide-tolerant crops) was rolled 
out irrespective of the consumer’s views or sentiments and in a man-
ner that was unreceptive to criticism or examination. Nowadays, 
the situation is different and the end-users are introduced to new 
technologies at a much earlier stage in development, with a view to 
obtaining social license for their use. In the case of Golden Rice, the 
first introduction the public had to this trait was through the front 
cover of Time magazine in 2000, proclaiming "This rice could save a 
million kids a year" (see Fig. 4 in ref. 13). Although this represented 
wide-reaching coverage, it also coincided with growing antago-
nism towards GM crops and plant genetic engineering, at least in 
Europe, where several well-organized non-governmental orga-
nizations focused efforts to critique and question the ethos of the 
Golden Rice project13. As recorded by the inventors of Golden Rice, 
this antipathy then radiated out to developing countries, includ-
ing the Philippines where the IRRI-led field trials of GR2 were 
subsequently vandalized12.
This poses the question as to why would anyone want to destroy 
a research project, especially one that could deliver great potential 
health benefits. It could be argued that people were unfamiliar or 
fearful of this new technology but could that explain such a reac-
tion? More likely, a few activists ideologically opposed to GM tech-
nology were able to project a loud and persuasive voice in support 
of their views, in the absence of facts to the contrary. The temp-
tation to fight fire with fire must be avoided — scientists are not 
spin-doctors or public relations experts but instead have a duty to 
report advances in a factual manner, not resorting to hype. This can 
seem bland and unexciting to the media looking to cover a story, 
especially in the face of hyperbolic claims from opponents.
It is important to be open, honest and transparent, presenting 
the facts as they are and not trying to avoid difficult issues. In our 
experience of carrying out omega-3 trait GM field trials in the UK20, 
effective communication to a wide and varied audience is essential; 
whilst effectively conveying the same facts about the research tailor-
ing the message to the recipient’s interests ensures engagement and 
the initiation of dialogue. Engagement in a two-way conversation, 
aiming to listen to the views, concerns and opinions of others and 
demonstrating a preparedness to respond to such concerns, in some 
instances even including the way that the research is conducted. For 
example, in 2014, at Rothamsted Research a public dialogue focus-
ing on the work of the organization with industry was conducted. 
The outcomes26 of this public dialogue exercise were used to inform 
the development of the organization’s knowledge exchange and 
commercialization strategy, which in turn guided the approach to 
translation of the omega-3 trait. Additionally, when the first per-
mission was granted to Rothamsted to conduct field trials of GM 
camelina in 2014, there was no requirement in terms of biosafety 
to cover the transgenic crop with a net. However, in discussions 
with neighbouring honey producers and commercial organic farm-
ers there were concerns raised about the pollen flow. In response to 
this, the crop was covered by a net during flowering to reassure the 
stakeholders that they had been heard. None of this guarantees that 
the public will be receptive to a new technology, nor should it be 
the sole motivation for such dialogue activities but it can help better 
frame innovation in a wider context. In addition, the responsible 
research and innovation framework that has been developed for 
use by Research Councils UK (now UK Research and Innovation, 
NATuRe PlANTS | www.nature.com/natureplants
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UKRI) and the communities they support27 has been extensively 
used in the recent stages of engagement for the omega-3 project at 
Rothamsted Research. Adoption of the responsible research and 
innovation principles was manifest through institutional commu-
nications and engagement strategy28. One could argue that in the 
omega-3 example at Rothamsted the research, the researchers and 
potentially the future consumer of the possible direct or indirect 
product have all benefited from the responsible research and inno-
vation process. In general, the move from experimental stages to 
commercialization and the associated opportunities for informed 
consumer choice, dictate, now more than ever, that social scientists 
have an important role to play alongside the research and develop-
ment teams. In the specific examples considered here, of nutrition-
ally enhanced crops developed to address health and malnutrition 
challenges, probably the need is even more pressing and relevant. 
It is worth noting that the omega-3 GM field trials have been tak-
ing place since 2014 in the UK without incidents of vandalism or 
protest and feedback from stakeholders has informed the design of 
the experiment in the field at different times. Being able to conduct 
these trials without disruption has enabled refinement and improve-
ment of the trait and brings it closer to commercial application, 
the route that can benefit the consumer and the environment.
Discussion
In this short article, we have not only tried to record the progress 
made by the two best-known examples of GM crops with enhanced 
nutritional properties but also to take a critical look at some of 
the factors that might have contributed to the slow progress in the 
application of fundamental research in this area. The primary issues 
can be listed as follows:
•	 intellectual property (freedom-to-operate, licensing, volume)
•	 economic value (viable business proposition versus social value)
•	 regulatory approval (cost, time)
•	 consumer and societal acceptance
From the perspective of private industry, who also represent the 
developers of virtually all deregulated (in other words, approved) 
and commercialized GM crops (predominantly input traits), the 
most important factor will be value and financial return. What of the 
situation for nutritional enhancement output traits? As discussed 
above, the academic developers of Golden Rice made it explicit that 
it should be not-for-profit but equally, the lack of an economic pull 
(in the form of monetizable consumer demand) could be an imped-
iment to faster progress. As evidence for this, although GR2 has 
recently gained regulatory approval process for food and feed use 
in some (non-target) countries such as Canada, USA and Australia, 
an omega-3 canola event making DHA was already approved for 
similar use by Food Standards Australia New Zealand in 2017 
and commercial cultivation in the USA in 2018 (ref. 21). However, 
there is hope that 2019 will see approval for cultivation of GR2E in 
Bangladesh, as well as regulatory field trials in the Philippines.
There is a pressing need for a different pathway by which health-
beneficial traits in GM plants are delivered to consumers, such that 
it is not reliant on market-forces and economics. This may need 
to be supported by the public purse rather than by private indus-
try but this would be offset by cost-savings to national health 
services as a result of a healthier population. In such a scenario, 
public funding would continue beyond the research phase, helping 
to navigate a project through regulatory approval and onto a level 
ready for consumer uptake and end-use. Such a scenario would 
only be applicable to examples where the technology demonstrably 
had the capacity to deliver meaningful improvements to diets and 
would still be dependent on societal acceptance. A scenario where 
the consumer would receive a tangible benefit (improved diet and 
health) and also be an actively involved stakeholder shaping the 
development of the technology/trait (as well as being a shareholder 
by contributing to its funding as a tax payer and funder of the pub-
lic purse) might be met with less resistance than a privately owned 
input trait. That good nutrition should be central to healthcare is a 
concept gaining traction7,29.
In the future, additional nutritional enhancement traits will 
probably progress and there are some promising examples—black 
tomatoes with extra anthocyanins, cereals fortified with vital 
micronutrients and maize stacked with several different extra vita-
mins7,30–32. Equally exciting is the emergence of a new generation 
of transgenic plants with nutritional enhancements, such as the 
aSTARice (which builds on Golden Rice). aSTARice can synthe-
size a tailored range of carotenoids and ketocarotenoids (such as 
astaxanthin and canthaxanthin) with health benefits primarily as 
Herbicide tolerance –17 years
Omega-3 canola – 21 years
Golden Rice >35 years
Average time for
agricultural innovation
– 28 years
Fig. 1 | Schematic representation of timelines for conversion of idea into innovation in agriculture. The length of the line is proportional to the indicated 
time in years between initial conception and application. In the case of Golden Rice the regulatory approval process is ongoing, hence the broken line. 
Timescales are described in the text. The omega-3 canola trait is described in ref. 21. Credits: Images adapted from Rothamstead Research Ltd (a,c) and 
from the image collection of the International Rice Research Institute (IRRI) (b).
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antioxidants33 and the eye-catching expression of betalain pigments 
that also act as potent antioxidants34. These are just a few examples, 
many still at the research phase but hopefully viable to make the 
transition to product. As Marc Van Montagu, one of the pioneers of 
plant biotechnology, notes ‘Genetically engineered plants and plant 
biotechnology have the potential to revolutionize agriculture in a 
sustainable manner; …and profoundly improve the health, quality 
of life and livelihood of mankind’35. To build on the present advances 
and successes, in addition to a vibrant research base, we need a cul-
ture of translation and impact, where even fundamental results are 
framed with a view to how they might be of use and benefit.
Before we conclude, it is important to note that the implementa-
tion of innovation, at least in agriculture, often takes time—on aver-
age just under 30 years36 and in many other cases a lot longer. For 
example, the first experiments to generate hybrid vigour in maize 
were successfully carried out in 1877 by William Beal (MSU) but 
it was not until 1933 that the first commercial plantings of hybrid 
maize occurred in the US. That the fastest example (at 17 years) of 
an agricultural innovation being translated into practice is the GM 
Roundup-Ready herbicide-tolerance trait demonstrates, at least in 
part, the potential of plant biotechnology36 (Fig. 1).

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